Icentia and the Institut Universitaire de Cardiologie et de Pneumologie de Québec to launch a 300-patient multicentric clinical study to evaluate the efficacy of the CardioStat

In collaboration with the Institut Universitaire de Cardiologie et de Pneumologie de Québec (IUCPQ), Icentia is embarking on a clinical study to evaluate the CardioStatTM, a unique electrocardiography solution for patients with suspected cardiac arrhythmia.

Specifically, the study will evaluate the performance of the CardioStatTM electrocardiography monitor and its efficacy at detecting most common types of atrial arrhythmias. In a three-phase, 2-year multi-center clinical study, set to begin this spring, approximately 300 patients will be enrolled and followed for suspected arrhythmia with the CardioStatTM electrocardiography monitor.

The study will be under the supervision of cardiologist Dr Isabelle Nault from IUCPQ. Dr Nault is the Principal Investigator. She will also be receiving the support from a group of six other cardiologists from IUCPQ. This study was made possible with the financial support of the Fondation de l'IUCPQ.

IUCPQ's mission is to stop epidemic obesity and the progression of cardiac and pulmonary diseases. Learn more at http://www.iucpq.qc.ca.

Icentia receives financial support from the Ministère des Finances et de l'Économie of the province of Quebec for the development of the CardioStat

QUEBEC, November 4, 2012 - Icentia is pleased to announce that it has won the support of the Ministère des Finances et de l'Économie of the province of Quebec through its Programme d'Appui à l'Innovation. This important contribution will support Icentia in the design of its electrocardiography recorder, CardioStatTM, and will assist with regulatory elements and intellectual property issues.

The main objective of the program is to support Quebec companies in the development and marketing of new products and innovative processes in technology.

For more information on the PAI program, click here.

About Icentia
Icentia is a combined medical devices and service company based in Canada. It develops a line of innovative solutions for healthcare institutions in the field of ambulatory electrocardiography and pulse oximetry. Icentia's mission is to help healthcare institutions become more efficient by providing unique solutions easing the process of medical testing.

Icentia and the Institut Universitaire de Cardiologie et de Pneumologie de Québec have agreed to collaborate in the testing of an innovative cardiac rhythm recorder.

QUEBEC, July 29, 2012 - Icentia and the Institut Universitaire de Cardiologie et de Pneumologie de Québec (IUCPQ) have agreed to collaborate for the testing of a unique electrocardiography monitoring solution for patients with suspected cardiac arrhythmia. This agreement will allow Icentia to benefit from IUCPQ's expertise during the device's development and will eventually lead to a clinical study to test efficacy.

For Icentia, involving such an important clinical partner at an early stage of a product development is a key element of its strategy. This approach ensures that healthcare institutions are provided with innovative, real-world solutions that are perfectly adapted to their requirements.

The IUCPQ is a leader in specialized and ultra-specialized care in cardiology. It is the healthcare center with the largest clinical volume in tertiary cardiology in Canada. IUCPQ's mission is to stop epidemic obesity and the progression of cardiac and pulmonary diseases. Learn more at http://www.iucpq.qc.ca.